Technical Data
010933
Dolutegravir
2.5mg
Biochemicals Storage: 4CShipping: RT
Dolutegravir is a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector.

Solubility:
As reported

Method for Determining Identity:
Proton NMR (DSMO-d6), 19F NMR (DSMO-d6) Spectroscopy and Mass Spectrometric Analysis

TLC Conditions:
As reported

Melting Point:
As reported

Storage and Stability:
May be stored at RT for short-term only. Long-term storage is recommended at 4C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.

Toxicity and Hazards:
All products should be handled by qualified personnel only, trained in laboratory procedures.

CAS Number:
1051375-16-6

Molecular Formula:
C20H19F2N3O5

Molecular Weight:
419.38
Purity: ~90%
Form: As reported

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Kobayashi, M. et al. Antimicrob Agents Chemother., 55, 813 (2011). 2. Garrido, C. et al.: Antiviral, Res., 90, 164 (2011). 3. Lenz, J.C.C. et al.: Exp. Opin. Invest. Drugs, 20, 537 (2011).

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.